Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tackling Resistance to PI3K Inhibition by Targeting the Epigenome.

Cancer cell - 8 May 2017

Koren Shany, Bentires-Alj Mohamed

Abstract excerpt

Phosphoinositide-3-kinase (PI3K) pathway inhibitors have emerged as promising therapeutic agents for estrogen receptor (ERα)-positive breast cancers. However, incipient resistance limits the clinical benefit. Toska and colleagues identified that the epigenetic regulator KMT2D enhances ERα activity in BYL719-treated PIK3CA mutant breast cancer, leading to a rationale for targeting the epigenome and PI3K signaling.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cell Line, Tumor
Share to Estrogen Receptor alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Protein Kinase Inhibitors

Share to Receptors, Estrogen

Share to Signal Transduction

Source

Identifiers

PMID: 28486103
DOI: 10.1016/j.ccell.2017.04.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tackling Resistance to PI3K Inhibition by Targeting the Epigenome.PMID 28486103Read ↗

Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancerSemantic proximity Read ↗

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.Semantic proximity Read ↗

Genomic Alterations in PIK3CA -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα InhibitorsSemantic proximity Read ↗

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerSemantic proximity Read ↗

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current AchievementsSemantic proximity Read ↗

PIKing the right patient.Semantic proximity Read ↗

Overview of the relevance of PI3K pathway in HR-positive breast cancerSemantic proximity Read ↗

CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphomaSemantic proximity Read ↗

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular PlasticitySemantic proximity Read ↗

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsSemantic proximity Read ↗

Exploiting an Epigenetic Resistance Mechanism to PI3 Kinase Inhibition in Leukemic Stem CellsSemantic proximity Read ↗

Targeting AML at the intersection of epigenetics and signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.